EndoGastric Solutions, Inc. (formerly known as EsophyX, Inc.) is a medical technology company that develops incisionless transoral procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease and other GI disorders.
It designs and manufactures EsophyX for use in endoluminal, transoral tissue approximation, thickness placation, and ligation in the GI tract. Its EsophyX is also indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. The company also offers Stomaphyx, a device for Natural Orifice Surgery, as well as for use in transoral tissue approximation and ligation in the GI tract.
The company markets EsophyX in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, Mexico, the Netherlands, South Africa, Spain, Portugal, the United Kingdom, and the United States; and Stomaphyx in the Czech Republic, Finland, Hungary, Poland, Slovenia, and Sweden.
EndoGastric Solutions, Inc. was founded in 2002 and is headquartered in Redmond, Washington. It has a location in Redwood City, California.
Latest funding size
Time since last funding
|about 1 year|
|Canaan Partners, Advanced Technology Ventures, Chicago Growth Partners, Foundation Medical Partners, MPM Capital, Radius Ventures, DeNovo Ventures, Oakwood Medical Investors, Flare Capital Partners, CRG|